Stereotactic ablative body radiotherapy for primary kidney cancer: What have we learned from prospective trials and what does the future hold?

Shankar Siva; Christopher P. Daniels; Rodney J. Ellis; Lee Ponsky; Simon S. Lo

doi:10.2217/fon.16.6

Stereotactic ablative body radiotherapy for primary kidney cancer: What have we learned from prospective trials and what does the future hold?

Shankar Siva, Christopher P. Daniels, Rodney J. Ellis, Lee Ponsky, Simon S. Lo

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	601-606
Number of pages	6
Journal	Future Oncology
Volume	12
Issue number	5
DOIs	https://doi.org/10.2217/fon.16.6
State	Published - Mar 2016

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.2217/fon.16.6

Cite this

@article{d617fc6f32ee4686bbe4b5dbaaf37df3,

title = "Stereotactic ablative body radiotherapy for primary kidney cancer: What have we learned from prospective trials and what does the future hold?",

author = "Shankar Siva and Daniels, \{Christopher P.\} and Ellis, \{Rodney J.\} and Lee Ponsky and Lo, \{Simon S.\}",

year = "2016",

month = mar,

doi = "10.2217/fon.16.6",

language = "English (US)",

volume = "12",

pages = "601--606",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Stereotactic ablative body radiotherapy for primary kidney cancer

T2 - What have we learned from prospective trials and what does the future hold?

AU - Siva, Shankar

AU - Daniels, Christopher P.

AU - Ellis, Rodney J.

AU - Ponsky, Lee

AU - Lo, Simon S.

PY - 2016/3

Y1 - 2016/3

UR - https://www.scopus.com/pages/publications/84959420856

UR - https://www.scopus.com/inward/citedby.url?scp=84959420856&partnerID=8YFLogxK

U2 - 10.2217/fon.16.6

DO - 10.2217/fon.16.6

M3 - Comment/debate

C2 - 26837548

AN - SCOPUS:84959420856

SN - 1479-6694

VL - 12

SP - 601

EP - 606

JO - Future Oncology

JF - Future Oncology

IS - 5

ER -

Stereotactic ablative body radiotherapy for primary kidney cancer: What have we learned from prospective trials and what does the future hold?

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this